Trial Profile

Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 19 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms CARMENA

Most Recent Events

04 Jun 2019 Results assessing different subgroups from the Carmena trial in patients with metastatic renal cell carcinoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology
02 Aug 2018 Results published in the Urology
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com